How much royalty is fair? Real ranges, and why they move
Two percent can be generous and ten percent can be a bargain. What decides the number, what typical ranges look like, and how to argue for yours without guessing.
Many technology licences land between 1 and 8 percent of net sales, with software, pharmaceuticals and medical devices often higher and commodity industrial processes lower. The rate moves with readiness, exclusivity, patent strength and how much of the product's value the technology creates. Upfront fees and milestones shift the balance.
There is no royalty rate table in the Patents Act, and anyone who tells you ‘the standard rate is five percent’ is guessing. But the number is not random either. It is the price of a share of future profit, and a few forces push it up or down in predictable ways.
Typical ranges, with honest caveats
Across published deals and industry surveys, many technology licences fall somewhere between 1 and 8 percent of net sales. Industrial processes and components in low-margin products tend to sit at the lower end. Software, diagnostics, medical devices and pharmaceuticals often sit higher, sometimes well into double digits for a late-stage drug. Treat these as a conversation starter, not a benchmark.
What pushes the rate up
High readiness, because the licensee spends less to reach market. Exclusivity, because the licensee gets a position no competitor can buy. Strong, granted patents in key markets. A technology that is the main reason customers buy the product, rather than one component among many. And a high-margin end product with room to share.
What pushes it down
Early-stage technology at TRL 3 or 4, where the licensee carries years of development risk. Pending or narrow patents. Non-exclusive rights. A technology that forms a small part of a larger product. Large upfront or milestone payments, which buy down the running royalty.
The old rule of thumb
You will hear of the ‘25 percent rule’: the licensor gets about a quarter of the licensee's expected profit from the product. Courts and economists have criticised it, and it should never be the only basis for a number. But as a sanity check, it is useful. If your royalty would take most of the licensee's margin, the deal will not survive its first bad year.
How to argue for your number
Build a simple model: expected sales, margin, the share of that margin the technology creates, and the cost and risk of getting to market. Then show your working. Negotiations go faster when both sides are arguing about assumptions rather than about a number someone pulled from the air.
Finally, think about structure, not just rate. A lower royalty with a meaningful minimum annual payment, a step-down after a sales threshold, or milestones tied to real events often serves both sides better than a single headline percentage.